PMID- 23638435
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130503
LR  - 20211021
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 3
DP  - 2013
TI  - Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for 
      Clinical Integration.
PG  - 93
LID - 10.3389/fonc.2013.00093 [doi]
LID - 93
AB  - Children with solid tumors represent a unique population. Recent improvements in 
      pediatric solid tumor survival rates have been confined to low- and moderate-risk 
      cancers, whereas minimal to no notable improvement in survival have been observed 
      in high-risk and advanced-stage childhood tumors. Treatments for patients with 
      advanced disease are rarely curative, and responses to therapy are often followed 
      by relapse, which highlights the large unmet need for novel therapies. Recent 
      advances in cancer treatment have focused on personalized therapy, whereby 
      patients are treated with agents that best target the molecular drivers of their 
      disease. Thus, a better understanding of the pathways that drive cancer or drug 
      resistance is of critical importance. One such example is the 
      phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) 
      pathway, which is activated in many solid cancer patients and represents a target 
      for therapy. PI3K/Akt/mTOR pathway activation has also been observed in tumors 
      resistant to agents targeting upstream receptor tyrosine kinases (RTKs). Agents 
      that target this pathway have the potential to shut down survival pathways, and 
      are being explored both in the setting of pathway-activating mutations and for 
      their ability to restore sensitivity to upstream signaling targeted agents. Here, 
      we examine the role of the PI3K/Akt/mTOR pathway in pediatric solid tumors, 
      review the novel agents being explored to target this pathway, and explore the 
      potential role of the inhibition of this pathway in the clinical development of 
      these agents in children.
FAU - Loh, Amos H P
AU  - Loh AH
AD  - Department of Surgery, St. Jude Children's Research Hospital Memphis, TN, USA.
FAU - Brennan, Rachel C
AU  - Brennan RC
FAU - Lang, Walter H
AU  - Lang WH
FAU - Hickey, Robert J
AU  - Hickey RJ
FAU - Malkas, Linda H
AU  - Malkas LH
FAU - Sandoval, John A
AU  - Sandoval JA
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC3636761
OTO - NOTNLM
OT  - Akt
OT  - PI3K
OT  - mTOR
OT  - pediatric solid tumors
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
PMCR- 2013/01/01
CRDT- 2013/05/03 06:00
PHST- 2012/12/27 00:00 [received]
PHST- 2013/04/05 00:00 [accepted]
PHST- 2013/05/03 06:00 [entrez]
PHST- 2013/05/03 06:00 [pubmed]
PHST- 2013/05/03 06:01 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2013.00093 [doi]
PST - epublish
SO  - Front Oncol. 2013 Apr 23;3:93. doi: 10.3389/fonc.2013.00093. eCollection 2013.